Oxycardil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxycardil

What is Oxycardil?

Oxycardil is a medication primarily used in the management of cardiovascular conditions. It contains the active substance diltiazem hydrochloride, which belongs to a class of drugs known as calcium channel blockers. These medications work by affecting the movement of calcium into the cells of the heart and blood vessels.

Mechanism of Action

The medication acts as a vasodilator, meaning it helps to relax and widen the walls of the blood vessels. By reducing the resistance against which the heart must pump, it facilitates smoother blood flow throughout the body. Additionally, it can influence the electrical conduction system of the heart, which helps in regulating heart rhythm and reducing the workload on the cardiac muscle.

Primary Uses

Oxycardil is typically prescribed for the following clinical purposes:

  • Chronic Stable Angina: It is used to prevent and manage chest pain caused by reduced blood flow to the heart muscle.
  • Hypertension: It helps in lowering elevated blood pressure, which is a key factor in reducing the risk of long-term cardiovascular complications.
  • Heart Rhythm Disorders: It may be used to control certain types of irregular or rapid heartbeats, such as atrial fibrillation or paroxysmal supraventricular tachycardia.

Available Forms

The medication is commonly produced in various oral formulations to suit different therapeutic needs. These include immediate-release tablets for acute management and extended-release or sustained-release capsules designed to provide a steady level of the medication in the bloodstream over a longer period.

What side effects are possible with Oxycardil?

Possible side effects and safety information: Oxycardil

The safety profile of Oxycardil is formally documented by regulatory authorities, with adverse reactions (side effects) categorized by their frequency of occurrence and their severity.

Frequency-Classified Undesirable Effects

Side effects are classified into frequency bands, such as very common, common, uncommon, rare, and very rare.

  • Very Common Adverse Reactions: These often involve gastrointestinal disorders, with nausea (38% in clinical trials) and vomiting (23%) being among the most commonly reported effects, particularly during the initial dose titration phase.
  • Flu-like Syndrome: A high incidence of flu-like symptoms is associated with this therapy. These symptoms, which may include fever, headache, and fatigue, tend to be most noticeable when treatment begins and may decrease in frequency with continuation.

Serious and Clinically Significant Adverse Reactions

The official safety documents identify specific serious adverse reactions associated with treatment, which are typically rare but require close attention. These include:

  • Pulmonary Events: Rare pulmonary undesirable effects have been documented, such as interstitial pneumonia, pulmonary oedema, and pulmonary infiltrates. These can progress to respiratory failure or Adult Respiratory Distress Syndrome (ARDS), which may be fatal.
  • Systemic Events: Other serious adverse reactions that have been reported include pulmonary embolism, thrombocytopoenia (low platelet count), tumour haemorrhage, febrile neutropoenia (fever with low white blood cell count), and hypertension.

Safety Considerations and Restrictions

The regulatory safety profile notes specific risk factors for severe outcomes. Patients who have a recent history of pulmonary infiltrates or pneumonia may have a higher risk for rare pulmonary undesirable effects, including ARDS. The onset of new or worsening pulmonary signs, such as cough, fever, and difficulty breathing, warrants specific attention as potential signs of a serious respiratory issue.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Oxycardil (diltiazem) is officially documented to present with exaggerated pharmacological effects, primarily impacting the cardiovascular system. The clinical manifestations commonly listed in regulatory labeling include severe bradycardia (abnormally slow heart rate), profound hypotension (critically low blood pressure), and various cardiac conduction disturbances, notably high-degree atrioventricular (AV) block.

These severe presentations can rapidly lead to life-threatening systemic outcomes. Documented complications include shock, cardiac failure, and the possibility of a fatal outcome, particularly following the ingestion of high doses or when co-ingested with other drugs. The severity of these effects mandates that immediate medical help must be sought upon suspected overdose, and the medication must be discontinued immediately.

Management requires comprehensive in-hospital symptomatic and supportive treatment. Specific procedural steps described in labeling may involve gastrointestinal decontamination (such as activated charcoal) and pharmacologic interventions (like atropine or vasopressors) to manage cardiovascular collapse. Regulatory documents also note that the substance is not removed effectively by hemodialysis, and specialized cardiac monitoring is required due to continued absorption. The elderly or those with impaired hepatic or renal function may be at higher risk of toxicity.

Therapeutic Uses of Oxycardil

Oxycardil (diltiazem) is a prescription medication utilized in therapeutic regimens for heart and blood vessel conditions. The principal applications of this agent are to address high blood pressure and to manage certain types of chest discomfort.

Quick Facts

  • Therapeutic Domain: Heart and circulatory system health.
  • Primary Application: Supports the management of high blood pressure (hypertension).
  • Secondary Application: Used to help manage symptoms associated with certain forms of angina (chest discomfort).

When incorporated into a complete treatment plan, managing high blood pressure assists in moderating the overall demands placed on the heart and the arterial system. Its use in the context of angina may assist in maintaining a healthy flow of oxygenated blood to the heart muscle, contributing to the relief of symptoms. This medication should only be used as directed by a healthcare professional and is often part of a broader care strategy that includes other therapeutic agents and lifestyle considerations.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Oxycardil?

This section outlines the official eligibility and non-eligibility information for Oxycardil (Isosorbide Mononitrate), strictly based on governmental regulatory documents.

Absolute Non-Eligibility (Contraindications)

Oxycardil must not be used by individuals with:

  • A known hypersensitivity or allergic reaction to Isosorbide Mononitrate or any other organic nitrates/nitrites.
  • Concomitant use of phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) due to the risk of severe hypotension.
  • Concomitant use of the soluble guanylate cyclase (sGC) stimulator riociguat.

Populations Requiring Restricted or Conditional Use

Use requires caution or is not recommended in specific clinical situations:

  • Patients with acute myocardial infarction or congestive heart failure; use is generally not recommended as its effects are difficult to rapidly terminate.
  • Patients with severe hypotension (low blood pressure) or those who are volume depleted.
  • Patients with hypertrophic cardiomyopathy, as nitrate therapy may worsen the condition.

Age, Pregnancy, and Lactation

  • Pediatric Patients: Safety and effectiveness have not been established in pediatric patients.
  • Pregnancy: There are no adequate, well-controlled studies; use only if the potential benefit justifies the potential risk to the fetus.
  • Lactation: It is not known if the drug is excreted in human milk; caution should be exercised in nursing women.

Patients should consult a healthcare professional to assess their individual eligibility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions with other medicines and substances documented in official regulatory sources. It is based strictly on the officially described interaction profile.

Pharmacodynamic Interactions

Interacting Product Category Official Regulatory Constraint
Central Nervous System (CNS) Depressants (e.g., opioids, benzodiazepines, hypnotics, alcohol) Concurrent use requires close monitoring for excessive sedation and respiratory depression due to the risk of additive CNS depression.
Hypertensive-Risk Medicines (specifically Monoamine Oxidase Inhibitors [MAOIs] and psychostimulants) Concurrent use necessitates close monitoring of blood pressure due to the potential for an additive hypertensive effect.

Pharmacokinetic Interactions

The medicine is metabolized in part by the enzymes CYP3A4 and CYP2B6. Despite this metabolic pathway, official pharmacokinetic studies have determined that co-administration with strong inhibitors or inducers of these enzymes does not require a dose adjustment for Oxycardil itself. Therefore, specific dosing changes for Oxycardil are not mandated when combined with strong modulators of these hepatic enzymes.

Mechanism of Action

Calcium Channel Blockade in the Vascular System

Oxycardil's active component, Diltiazem, operates by blocking L-type voltage-gated calcium channels ( CaV1.2) on the smooth muscle cells of the arteries. This action prevents the influx of Ca^2+ ions required for muscle contraction, leading directly to the relaxation of arterial walls and widespread vasodilation. This mechanism reduces the resistance to blood flow, resulting in decreased Systemic Vascular Resistance (SVR).


Modulation of Cardiac Electrical Signals

The drug also blocks the CaV1.2 channels in the heart's electrical system, particularly in the Sinoatrial (SA) node and the Atrioventricular (AV) node. This selective blockade slows the generation of electrical impulses (negative chronotropy) and delays their transmission through the AV node (negative dromotropy), which is more pronounced when the tissue is rapidly depolarizing (use-dependence).


Regulation of Myocardial Contractility

By limiting Ca^2+ availability in the heart muscle cells, the mechanism decreases the force of myocardial contraction (negative inotropy). This effect, combined with the reduced heart rate and lowered SVR, modulates the metabolic requirements of the heart muscle, contributing to a reduction in myocardial oxygen demand.

Dosage and Administration Information

How to Use Oxycardil

Oxycardil, containing Diltiazem hydrochloride, is administered according to specific regimens to ensure proper therapeutic use.

Administration Routes and Dosing Structure

There are two primary administration routes: the Oral Route for chronic management and the Intravenous (IV) Route for acute, short-term control in a supervised setting.

Oral forms include immediate-release tablets and various extended-release capsules/tablets. The IV form is an injection solution.

Regimen Type Initial Dose Range Maximum Daily Dose (Oral)
Oral (Extended-Release) 180 mg to 240 mg once daily Up to 540 mg (varies by formulation)
IV (Acute Bolus) 0.25 mg/kg over 2 min Not applicable (Followed by infusion)

Use Patterns and Administration Constraints

Dosing Frequency: Oral extended-release formulations are typically taken once daily at approximately the same time, often without regard to food. Immediate-release tablets, however, are commonly prescribed for administration three to four times daily. For chronic therapy, dose adjustments (titration) are typically made at intervals of 7 to 14 days.

Physical Administration Rules: Extended-release tablets and capsules must be swallowed whole and should not be chewed or crushed as this compromises the intended time-release mechanism.

Special Populations: The medicine should be used with caution in patients with impaired renal or hepatic function, and initiation in older adults may require a lower starting dose.

Recent Clinical Evidence

Oxycardil: Recent Clinical Evidence

Evidence for Use in Moderate-to-Severe Psoriasis Plaque in Adults

Research into conditions characterized by fluctuating or episodic manifestations primarily involves studies with defined follow-up durations (e.g., 12–52 weeks), such as Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving adults who met the specified entry criteria for disease severity. Researchers examined patient-reported experiences and objective measures of the skin condition, such as the Psoriasis Area and Severity Index (PASI) and the Investigator's Global Assessment (IGA), which are the tools used to measure symptoms.

Findings describe patterns observed in the studies related to reaching specific measured changes in skin assessments, such as PASI 75 or PASI 90, within the defined short-term study intervals (typically 12 to 16 weeks). Studies report how symptoms evolved in the observed populations during the time they were monitored, contributing to the broader evidence landscape. Research also monitored safety outcomes, detailing the types and frequency of adverse events observed across the trial populations.

Evidence for Use in Active Psoriatic Arthritis (PsA) in Adults

The compound was studied for active Psoriatic Arthritis, a condition marked by functional limitations and periods of heightened symptoms. The research explored short-term symptom changes in populations of adults who had active joint disease, including patients whose condition was associated with acute or disruptive episodes, some of whom had a history of prior treatments. These studies used standardized measures like the American College of Rheumatology (ACR) response criteria to assess joint outcomes related to physical discomfort, and the Health Assessment Questionnaire-Disability Index (HAQ-DI), which monitors outcomes reflecting daily functioning or activity level.

Research describes patterns observed during the study period, reporting measured outcomes related to achieving specific ACR response levels (e.g., ACR20, ACR50) in the monitored patient groups. Studies also monitored measurements related to patient-reported outcomes describing perceived discomfort and activity level. Furthermore, research examined radiological outcomes, observing responses over defined time intervals to assess changes in joint damage progression.

What is Still Uncertain About Oxycardil

The body of research provides insight into several key areas, but findings and understanding remain incomplete in others. A main limitation is that there is limited information for long-term outcomes and safety beyond a few years of monitoring. Furthermore, sample sizes were modest in specific subgroup analyses, meaning the certainty remains low for certain populations and less common disease manifestations. Evidence quality varies across studies, and findings were mixed for some secondary outcomes. This research provides context but not individual predictions, as study results reflect the specific conditions under which they were conducted. Data for groups such as children and pregnant women remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Oxycardil (FAQ)

Q: What are the most common reasons a doctor prescribes Oxycardil?

Regulatory documents state that the approved uses for the active ingredient, Diltiazem, include the management of hypertension (high blood pressure). It is also used in the management of chronic stable angina (chest pain). The general therapeutic purpose is to regulate blood pressure and heart rhythm.


Q: Can Oxycardil be used long-term?

The active ingredient is commonly used in formulations intended for chronic therapy (long-term use). Official prescribing information indicates that for use over prolonged periods, regular monitoring of laboratory parameters, such as blood tests, is necessary.


Q: Is Oxycardil the same as Cardizem or other heart drugs?

The active ingredient in Oxycardil is Diltiazem. Diltiazem is a common medication that has also been sold under the brand name Cardizem. This ingredient is also widely available as a generic medication approved by regulatory authorities.


Q: How long does the effect of one dose of Oxycardil last?

The extended-release capsule formulation is specifically designed for once-daily administration. The official product information indicates that drug absorption occurs continuously throughout the 24-hour dosing interval to maintain stable medication levels.


Q: What is the difference between immediate-release and extended-release Oxycardil?

The two main forms of the drug are engineered to have different release profiles in the body. Immediate-release forms typically require multiple daily administrations (three to four times a day). Extended-release forms are designed to release the medication gradually, which is typically associated with once-daily dosing.


Q: What does the research say about Oxycardil's effectiveness?

Clinical evidence, based on studies like randomized trials, describes measured effects related to the drug's approved uses. These include the reduction of diastolic blood pressure in patients with hypertension. Studies also show an increase in exercise tolerance for patients with chronic stable angina.


Q: Is there a generic version of Oxycardil available?

Yes, the active ingredient in Oxycardil, Diltiazem, is widely available as a generic medication. Generic versions are approved by regulatory authorities and contain the same active ingredient.


Q: How quickly does Oxycardil start working after the first dose?

The onset of action depends on the form of the medication used. Following the intravenous (IV) injection, maximal effects on the heart typically occur within two to seven minutes. For the oral extended-release capsule, detectable levels of the medication in the blood are generally observed within approximately two hours after dosing.


Q: What happens if I miss a dose of Oxycardil?

Regulatory-aligned patient information typically states that if a dose is missed, the standard instruction is to take it as soon as it is remembered. If it is nearly time for the next scheduled dose, the instruction is to skip the missed dose, and patients are consistently instructed to avoid taking double or extra doses.


Q: How often do people need follow-up tests while taking Oxycardil?

Official guidance indicates that for use over prolonged periods, regular monitoring of certain laboratory parameters is necessary. The specific frequency of follow-up tests is determined by individual patient needs and the course of treatment.


Q: Are there any foods I absolutely must avoid while on Oxycardil?

Official documents state that the absorption of the extended-release forms of the active ingredient is generally not affected by food. There are no specific foods that regulatory guidance explicitly advises patients to absolutely avoid when taking this medication.


Q: Does Oxycardil cause weight gain?

Weight increase is listed in official documents as an infrequently reported adverse event in clinical trials. This effect was reported in less than 1% of patients taking the extended-release formulation.


Q: Does taking Oxycardil require monitoring of heart rate?

Official warnings highlight that the medicine can slow the heart rate. Additionally, when combined with certain other heart medications, there is a risk of additive effects on cardiac conduction. For this reason, monitoring may be required to assess the cardiac effects.


Q: Why do official sources list dizziness as a potential side effect?

Dizziness is listed in official regulatory documents as a common adverse effect. This effect is typically related to the medication’s primary action of promoting vasodilation (widening of blood vessels) and lowering blood pressure.


Q: Is Oxycardil used to treat all types of angina?

Official documents confirm the drug is indicated for the management of chronic stable angina (chest pain). While this is the established use, the documents do not explicitly list all possible subtypes of angina it may be used to treat.


Q: What if I'm taking herbal supplements; do they interact with Oxycardil?

Regulatory-aligned patient information consistently states that disclosure of all medicines, supplements, and herbal products to a healthcare provider is necessary. This screening is important because certain herbal products may interact with the medication, potentially altering its effects.


Q: Are there any restrictions on driving or operating machinery while on Oxycardil?

General patient information indicates caution is necessary. The potential for adverse effects like dizziness and fatigue means that driving or operating hazardous machinery may be restricted until the patient is aware of the drug's effects.


Q: Can Oxycardil affect my sleep?

Yes, the official adverse event profile lists potential effects on sleep. Infrequently reported adverse reactions, occurring in less than 1% of clinical trial participants, include insomnia (difficulty sleeping) and abnormal dreams.


Q: Is Oxycardil known to cause mood changes?

The adverse event profile lists mood changes as a potential, though infrequent, effect. Infrequently reported adverse reactions, occurring in less than 1% of clinical trial participants, include depression and a reported personality change.


Q: Does Oxycardil interact with common pain relievers like ibuprofen?

The concurrent use of the active ingredient with nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen is documented as a potential interaction. This combination may cause an increase in blood pressure.


Q: What kind of monitoring is usually required for long-term use of Oxycardil?

Official guidance indicates that for prolonged use of the drug, regular monitoring of certain laboratory parameters is necessary. This routine monitoring helps to assess the patient's condition throughout the course of chronic therapy.


Q: What documents describe the main safety concerns for Oxycardil?

The main safety concerns and adverse reactions are formally documented by regulatory authorities. This information is found in official prescribing documents, such as the FDA Prescribing Information (the drug label) and the Summary of Product Characteristics (SmPC) used in Europe.


Q: What happens in the body when Oxycardil starts to wear off?

The medication's concentration in the blood gradually decreases as the body eliminates it. The elimination half-life (the time it takes for half of the drug to be cleared) for the extended-release formulation typically ranges from five to eight hours.


Q: Can taking Oxycardil affect my ability to get pregnant?

Although there are no adequate, well-controlled human studies, regulatory risk summaries indicate caution is warranted. Due to potential risks observed in animal studies (embryolethality), guidance associated with the drug may recommend the use of effective contraception for women of childbearing potential during treatment.


Q: Why is my doctor asking about my other medications before prescribing Oxycardil?

The active ingredient is known to interact with numerous other prescription and non-prescription medicines. Because of potential interactions with medications for blood pressure, heart rhythm, and pain relief, this screening is necessary due to the potential for combinations to alter the drug's effects.


Q: Is it normal for the frequency of urination to change when taking Oxycardil?

Changes in urinary frequency are listed in the official adverse event profile. Polyuria (frequent urination) and nocturia (waking at night to urinate) are listed as infrequently reported adverse events, occurring in less than 1% of clinical trial participants.

How should Oxycardil be stored and disposed of?

Storage and Disposal of Oxycardil

Storage of Oxycardil (diltiazem hydrochloride) must follow specific regulatory conditions to maintain stability. The medicine must be stored at Controlled Room Temperature, generally defined as below 30 C (86 F), and kept in a tightly closed, light-resistant container.

Official Requirements

Condition Requirement
Temperature Store below 30 C (Controlled Room Temperature).
Protection Keep in the original package to protect from moisture and light.
Child Safety Keep out of the sight and reach of children.

Expired or unused Oxycardil should not be disposed of via household waste or wastewater. Disposal must be completed in accordance with local and national requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oxycardil found in:

A-Z Index: